PD-1
Assets acting on this target.
- Class
- Anti-PD-1 checkpoint inhibitor
- Notes
- original target text: PD-1 | original target text: PD-1 (inhibitor)
Programmed cell death protein 1 (PD-1) is a receptor found on the surface of activated T cells, the white blood cells responsible for recognizing and destroying abnormal or infected cells. When PD-1 binds its ligands, PD-L1 or PD-L2, it delivers an inhibitory signal that dampens T-cell activity. This checkpoint exists physiologically to prevent excessive immune responses and autoimmunity, but many tumors exploit it by expressing PD-L1 to suppress the T cells that would otherwise attack them. Blocking PD-1, typically with monoclonal antibodies that occupy the receptor and prevent ligand binding, releases this brake and allows T cells to resume recognizing and killing cancer cells. This approach, known as checkpoint inhibition, has become a foundational strategy across many solid tumors and some hematologic cancers, often used alone or combined with chemotherapy, radiation, or other immune-modulating agents. Because the mechanism restores a natural immune function rather than introducing a new one, its effects can be durable in patients who respond, though the same removal of an inhibitory checkpoint can also unmask immune activity against normal tissues, producing inflammatory side effects. PD-1 remains one of the most extensively targeted immune checkpoints in oncology, illustrating how modulating regulatory signals in the immune system can be harnessed against disease.
By indication
PD-1 drugs compared
27 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Cemiplimab | Regeneron Pharmaceuticals | monoclonal antibody | Approved | Approved in Non-Small Cell Lung Cancer; Phase 3 in Melanoma |
| Dostarlimab | GlaxoSmithKline | monoclonal antibody | Approved | Approved in Endometrial Cancer; Approved in Rectal Cancer; Phase 3 in Non-Small Cell Lung Cancer |
| Nivolumab | Bristol-Myers Squibb, Ono Pharmaceutical | monoclonal antibody | Approved | Approved in Advanced Metastatic Colorectal Cancer; Approved in Colorectal Cancer; Approved in Esophageal Squamous Cell Carcinoma; Approved in Gastric Cancer; Approved in Head and Neck Squamous Cell Carcinoma; Approved in Hepatocellular Carcinoma; Approved in Melanoma; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Renal Cell Carcinoma; Approved in Urothelial Carcinoma |
| Opdivo Qvantig | Bristol-Myers Squibb | monoclonal antibody | Approved | Approved in Advanced Colorectal Cancer; Approved in Advanced Metastatic Colorectal Cancer; Approved in Colorectal Cancer; Approved in Esophageal Squamous Cell Carcinoma; Approved in Gastric Cancer; Approved in Head and Neck Squamous Cell Carcinoma; Approved in Hepatocellular Carcinoma; Approved in Melanoma; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Renal Cell Carcinoma; Approved in Urothelial Carcinoma |
| Pembrolizumab | Merck & Co. | monoclonal antibody | Approved | Approved in Biliary Tract Cancer; Approved in Breast Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Endometrial Cancer; Approved in Esophageal Squamous Cell Carcinoma; Approved in Gastric Cancer; Approved in Head and Neck Squamous Cell Carcinoma; Approved in Hepatocellular Carcinoma; Approved in Large B-Cell Lymphoma; Approved in Melanoma; Approved in Merkel Cell Carcinoma; Approved in Metastatic Colorectal Cancer; Approved in Non-Muscle Invasive Bladder Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Ovarian Cancer; Approved in Renal Cell Carcinoma; Approved in Solid Tumors; Approved in Urothelial Carcinoma; Phase 3 in HR+/HER2- Metastatic Breast Cancer |
| Pembrolizumab berahyaluronidase alfaKeytruda Qlex | Merck & Co. | monoclonal antibody | Approved | Approved in Bladder Cancer; Approved in Breast Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Gastric Cancer; Approved in Melanoma; Approved in Non-Small Cell Lung Cancer; Approved in Renal Cell Carcinoma; Approved in Solid Tumors |
| Penpulimab | Akeso, Chia Tai Tianqing Pharmaceutical Group | monoclonal antibody | Approved | Approved in Nasopharyngeal Carcinoma; Phase 3 in Hepatocellular Carcinoma; Phase 3 in Non-Small Cell Lung Cancer |
| Retifanlimab | Incyte | monoclonal antibody | Approved | Approved in Merkel Cell Carcinoma; Approved in Squamous Cell Carcinoma of the Anal Canal; Phase 3 in Non-Small Cell Lung Cancer |
| Tislelizumab | BeOne Medicines | monoclonal antibody | Approved | Approved in Esophageal Squamous Cell Carcinoma; Approved in Gastric Cancer; Phase 3 in Nasopharyngeal Carcinoma; Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Small Cell Lung Cancer |
| Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | monoclonal antibody | Approved | Approved in Nasopharyngeal Carcinoma; Phase 3 in Cholangiocarcinoma; Phase 3 in Non-Small Cell Lung Cancer |
| Abp 234 | Amgen | monoclonal antibody | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| BAT3306 | Bio-Thera Solutions | monoclonal antibody | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Camrelizumab | Elevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticals | monoclonal antibody | Phase 3 | Phase 3 in Gastric Cancer; Phase 3 in Hepatocellular Carcinoma; Phase 3 in Nasopharyngeal Carcinoma; Phase 3 in Non-Small Cell Lung Cancer; Phase 2/3 in Cervical Cancer |
| Cetrelimab | Johnson & Johnson | monoclonal antibody | Phase 3 | Phase 3 in Bladder Cancer; Phase 1/2 in Non-Small Cell Lung Cancer |
| CT-P51 | Celltrion | monoclonal antibody | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Enlonstobart | CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Hangzhou Sumgen Biotech Co., Ltd. | monoclonal antibody | Phase 3 | Phase 3 in Cervical Cancer; Phase 3 in Non-Small Cell Lung Cancer |
| Iparomlimab (QL1604) | Qilu Pharmaceutical | monoclonal antibody | Phase 3 | Not recorded |
| MB12 | Laboratorio Elea Phoenix S.A., mAbxience Research S.L. | monoclonal antibody | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Serplulimab | Abbott, Accord Healthcare, Eisai, Intas Pharmaceuticals, Kalbe Genexine Biologics, Lotus Pharmaceutical Co., Ltd., Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., Shanghai Henlius Biotech | monoclonal antibody | Phase 3 | Phase 3 in Gastric Cancer; Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Small Cell Lung Cancer |
| Sintilimab | Innovent Biologics | monoclonal antibody | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Budigalimab | AbbVie | monoclonal antibody | Phase 2/3 | Phase 2/3 in Non-Small Cell Lung Cancer; Phase 2 in Urothelial Carcinoma |
| Sasanlimab | Pfizer | monoclonal antibody | Phase 2/3 | Phase 2/3 in Non-Small Cell Lung Cancer |
| Balstilimab | Agenus Inc., Zydus Lifesciences | monoclonal antibody | Phase 2 | Phase 2 in Cervical Cancer; Phase 2 in Non-Small Cell Lung Cancer |
| SHR-3045 | Jiangsu Hengrui Pharmaceuticals | undisclosed | Phase 2 | Phase 2 in Rheumatoid Arthritis |
| IOV-4001 | Iovance Biotherapeutics | cell therapy | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| OSE-279 | OSE Immunotherapeutics | monoclonal antibody | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| Bmab1700 | Biocon Biologics | monoclonal antibody | Phase 1 | Not recorded |